Back to top

messenger-rna: Archive

Zacks Equity Research

Moderna (MRNA) Lags on Q4 Earnings, COVID Jab Sales Down Y/Y

Moderna's (MRNA) fourth-quarter earnings and sales miss expectations. Management reiterates guidance to record a minimum of $5 billion from COVID vaccine sales in 2023.

MRKPositive Net Change VRTXPositive Net Change MRNAPositive Net Change EFTRNo Net Change

Zacks Equity Research

Moderna (MRNA) to Report Q4 Earnings: What's in the Cards?

Investors focus will likely be on Moderna's (MRNA) pipeline, especially with its late-stage pipeline candidates, when it reports fourth-quarter earnings.

MRKPositive Net Change BAYRYPositive Net Change MRNAPositive Net Change ALLOPositive Net Change

Zacks Equity Research

Vertex (VRTX) Beats on Q4 Earnings & Sales, '23 View Encouraging

Vertex Pharmaceuticals' (VRTX) four-quarter 2022 earnings and sales beat estimates. VRTX also issues better-than-expected revenue guidance for 2023.

VRTXPositive Net Change MRNAPositive Net Change CRSPPositive Net Change RCUSPositive Net Change

Zacks Equity Research

Vertex (VRTX) to Report Q4 Earnings: What's in the Cards?

On Vertex Pharmaceuticals' (VRTX) Q4 earnings call, investors will likely focus on the sales performance of its cystic fibrosis medicines and updates on its non-CF pipeline candidates.

VRTXPositive Net Change SNDXPositive Net Change CRSPPositive Net Change RCUSPositive Net Change